IDSA 2026 Gram-Negative Infection Guidelines
The IDSA published comprehensive guidance in 2026 specifically addressing antimicrobial-resistant gram-negative infections, providing treatment recommendations for ESBL-producing Enterobacterales, AmpC-producing Enterobacterales, carbapenem-resistant Enterobacterales (CRE), difficult-to-treat resistant Pseudomonas aeruginosa (DTR P. aeruginosa), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia 1.
Key Pathogens Covered
The 2026 IDSA AMR Guidance targets six major categories of resistant gram-negative organisms:
- ESBL-producing Enterobacterales (ESBL-E)
- AmpC β-lactamase-producing Enterobacterales (AmpC-E)
- Carbapenem-resistant Enterobacterales (CRE)
- Difficult-to-treat resistant P. aeruginosa (DTR P. aeruginosa)
- Carbapenem-resistant A. baumannii (CRAB)
- Stenotrophomonas maltophilia
Treatment Framework
The guidance provides both preferred and alternative treatment strategies based on:
- Pathogen identification
- In vitro susceptibility testing results
- Geographic considerations (focused on U.S. practice patterns)
- Both adult and pediatric populations (though specific dosing only provided for adults)
Empiric Therapy Considerations
For empiric coverage of suspected gram-negative infections, the guidance addresses:
- Initial antibiotic selection before culture results
- Transition to oral therapy when appropriate
- Duration of treatment recommendations
- Management considerations specific to infection site
Integration with Hospital-Acquired Pneumonia Guidelines
For gram-negative pneumonia specifically, the 2016 IDSA/ATS HAP/VAP guidelines remain relevant and recommend 2:
Risk Factors for MDR Gram-Negative Pathogens
- Prior intravenous antibiotic use within 90 days (strongest predictor)
- Septic shock at time of VAP
- ARDS preceding VAP
- Five or more days of hospitalization prior to VAP
- Acute renal replacement therapy prior to VAP onset
Empiric Antipseudomonal Coverage Strategy
For HAP patients, prescribe antibiotics with activity against P. aeruginosa and other gram-negative bacilli 2.
Use dual antipseudomonal coverage (two different antibiotic classes) when:
- Prior IV antibiotic use within 90 days
- High mortality risk (ventilatory support needed, septic shock)
- Structural lung disease (bronchiectasis, cystic fibrosis)
Single antipseudomonal agent acceptable for all other HAP patients without these risk factors 2.
Specific Antibiotic Options for Gram-Negative Coverage
β-lactam-based agents:
- Piperacillin-tazobactam 4.5 g IV q6h
- Cefepime 2 g IV q8h
- Ceftazidime 2 g IV q8h
- Carbapenems: Meropenem 1 g IV q8h or Imipenem 500 mg IV q6h
- Aztreonam 2 g IV q8h (can combine with another β-lactam due to different cell wall targets)
Non-β-lactam agents (for dual coverage):
- Ciprofloxacin 400 mg IV q8h
- Aminoglycosides: Amikacin 15-20 mg/kg IV q24h, Gentamicin 5-7 mg/kg IV q24h, or Tobramycin 5-7 mg/kg IV q24h
- Polymyxins (reserved for high MDR prevalence settings with local expertise)
Critical Caveats
Never use aminoglycosides as sole antipseudomonal agent - meta-analysis showed lower clinical response rates 2.
Never use aminoglycoside monotherapy for definitive P. aeruginosa treatment 2.
For VAP due to gram-negatives susceptible only to aminoglycosides or polymyxins, use both inhaled and systemic antibiotics rather than systemic alone 2.
Pharmacokinetic/Pharmacodynamic Optimization
Determine antibiotic dosing using PK/PD data rather than manufacturer's prescribing information alone 2. This includes:
- Extended or continuous infusions of β-lactams
- Weight-based dosing for specific antibiotics
- Therapeutic drug monitoring when appropriate
Definitive Therapy
Base definitive therapy on antimicrobial susceptibility testing results, not empiric coverage patterns 2. This reduces unnecessary broad-spectrum exposure and selection pressure for resistance.
Document Currency
This guidance is current as of March 1,2026, and will be updated periodically 1. The most current version is available at www.idsociety.org/practice-guideline/amr-guidance/.
Geographic Considerations
The IDSA AMR Guidance specifically focuses on U.S. clinical practice due to geographic variability in antimicrobial resistance epidemiology and antibiotic availability 1. Local antibiograms and resistance patterns should guide empiric therapy decisions.